CA2458699A1 - Novel dihydropteridinones, method for producing the same and the use thereof as medicaments - Google Patents
Novel dihydropteridinones, method for producing the same and the use thereof as medicaments Download PDFInfo
- Publication number
- CA2458699A1 CA2458699A1 CA002458699A CA2458699A CA2458699A1 CA 2458699 A1 CA2458699 A1 CA 2458699A1 CA 002458699 A CA002458699 A CA 002458699A CA 2458699 A CA2458699 A CA 2458699A CA 2458699 A1 CA2458699 A1 CA 2458699A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- denotes
- group selected
- optionally substituted
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The invention relates to novel dihydropteridinones of general formula (I), wherein the groups X, R1, R2, R3, R4, R5 and R7 are defined as per the claim s and the description, to the isomers thereof, to a method for producing said dihydropteridinones and to the use thereof as medicaments.
Claims (12)
1 ) Compounds of general formula (I), wherein R1 denotes a group selected from among hydrogen, NH2, XH, halogen and a C1-C3-alkyl group optionally substituted by one or more halogen atoms, R2 denotes a group selected from among hydrogen, CHO, XH, -X-C1-C2-alkyl and an optionally substituted C1-C3-alkyl group, R3, R4 which may be identical or different denote a group selected from among optionally substituted C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, aryl, heteroaryl, C3-C8-cycloalkyl, C3-C8-heterocycloalkyl, -X-aryl, -X-heteroaryl, -X-cycloalkyl, -X-heterocycloalkyl, -NR8-aryl, -NR8-heteroaryl, -NR8-cycloalkyl, - and -NR8-heterocycloalkyl, or a group selected from among hydrogen, halogen, COXR8, CON(R8)2, COR8 and XR8, or R3 and R4 together denote a 2- to 5-membered alkyl bridge which may contain 1 to 2 heteroatoms, R5 denotes hydrogen or a group selected from among optionally substituted C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, aryl, heteroaryl and -C3-C6-cycloalkyl , or R3 and R5 or R4 and R5 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms, R6 denotes optionally substituted aryl or heteroaryl, R7 denotes hydrogen or -CO-X-C1-C4-alkyl, and X in each case independently of one another denotes O or S, R8 in each case independently of one another denotes hydrogen or a group selected from among optionally substituted C1-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl and phenyl, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
2) Compounds according to claim 1, wherein X and R6 have the meaning indicated, and R1 denotes hydrogen, R2 denotes a group selected from among a CHO, OH, and CH3 group, R3, R4 which may be identical or different denote a group selected from among hydrogen, optionally substituted C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-cycloalkyl, or R3 and R4 together denote a C2-C5-alkyl bridge , R5 denotes a group selected from among optionally substituted C1-C10-alkyl, C2-C10-alkenyl, C2-C10-alkynyl, C3-C6-cycloalkyl and C3-C6-cycloalkenyl, or R3 and R5 or R4 and R5 together denote a saturated or unsaturated C3-C4-alkyl bridge which may contain 1 to 2 heteroatoms, and R7 denotes hydrogen, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
3) Compounds according to claim 1 or 2, wherein R1-R5, R7, R8 and X have the meaning indicated, and R6 denotes a group of general formula wherein n denotes 1, 2, 3 or 4, R9 denotes a group selected from among optionally substituted C1-C6-alkyl, C2-alkenyl, C2-C6-alkynyl, -CONH-C1-C10-alkylene, -O-aryl, -O-heteroaryl, -O-cycloalkyl, -O-heterocycloalkyl, aryl, heteroaryl, cycloalkyl and heterocycloalkyl or a group selected from among -O-C1-C6-alkyl-Q1, -CONR8-C1-C10-alkyl-Q1, -CONR8-C2-C10-alkenyl-Q1, -CONR8-Q2, halogen, OH, -SO2R8, -SO2N(R8)2, -COR8, -COOR8,-N(R8)2, -NHCOR8, CONR8OC1-C10 alkylQ1 and CONR8OQ2, Q1 denotes hydrogen, -NHCOR8, or a group selected from among an optionally substituted -NH-aryl, -NH-heteroaryl, aryl, heteroaryl, C3-C8-cycloalkyl- and heterocycloalkyl group, Q2 denotes hydrogen or a group selected from among an optionally substituted aryl, heteroaryl, C3-C8-heterocycloalkyl, C3-C8-cycloalkyl- and C1-C4-alkyl-C3-cycloalkyl group, R10 which may be identical or different denotes a group selected from among optionally substituted C1-C6-alkyl , C2-C6-alkenyl and C2-C6-alkynyl, -O-C1-C6-alkyl, -O-C2-C6-alkenyl, -O-C2-C6-alkynyl, C3-C6-heterocycloalkyl and C2-C6-cycloalkyl, or a group selected from among hydrogen, -CONH2, -COOR8, -OCON(R8)2, -N(R8)2, -NHCOR8, -NHCON(R8)2 , -NO2 and halogen, or adjacent groups R9 and R10 together denote a bridge of general formula Y denotes O, S or NR11, m denotes 0, 1 or 2 R11 denotes hydrogen or C1-C2-alkyl, and R12 denotes hydrogen or a group selected from among optionally substituted phenyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, -C1-C3-alkyl-phenyl, -C1-C3-alkyl-pyridyl, -C1-C3-alkyl-pyrazinyl, -C1-C3-alkyl-pyrimidinyl and -C1-C3-alkyl-pyridazinyl, R13 denotes C1-C6-alkyl optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
4) Compounds according to one of claims 1 to 3, wherein R3-R6, R8 and X have the meaning indicated, and R1 denotes hydrogen, R2 denotes CH3 , and R7 denotes hydrogen, optionally in the form of the tautomers, the racemates, the enantiomers, the diastereomers and the mixtures thereof, and optionally the pharmacologically acceptable acid addition salts thereof.
5) Compound of formula I according to one of claims 1 to 4 for use as pharmaceutical compositions.
6) Compound of formula I according to one of claims 1 to 4 for use as pharmaceutical compositions with an antiproliferative activity.
7) Use of a compound of formula I for preparing a pharmaceutical composition for the treatment and/or prevention of cancer, infections, inflammatory and autoimmune diseases.
8) Method of treating and/or preventing cancer, infections, inflammatory and autoimmune diseases, characterised in that a patient is given an effective quantity of a compound of formula I according to claims 1 to 4.
9) Pharmaceutical preparations, containing as active substance one or more compounds of general formula (I) according to one of claims 1 to 4 or the physiologically acceptable salts thereof, optionally combined with conventional excipients and/or carriers.
10) Process for preparing a compound of general formula (I), wherein R1-R7 and X have the meanings given in claims 1 to 4, characterised in that a compound of general formula (II) wherein R1-R5 and X have the meanings given in claims 1 to 4 and L is a leaving group, is reacted with an optionally substituted compound of general formula (III) wherein R6 and R7 have the meanings given in claims 1 to 4.
11) Compound of formula (II), wherein R1-R5 and X have the meanings given in claims 1 to 4.
12) Process for preparing a compound of general formula (1), wherein R6 denotes a group of general formula, R9 denotes an optionally substituted group -CONH-C1-C10-alkylene or a group selected from among -CONR8-C1-C10-alkyl-Q1, -CONR8-C2-C10-alkenyl-Q1, -CONR8-Q2, and -COOR8, and R1-R5, R7, R10, n and X are as defined as in claims 1 to 4, characterised in that a compound of general formula (IA) wherein R1 to R5, R7, R10 and n are as defined as in claims 1 to 4, and L denotes a leaving group, is reacted with a primary or secondary amine to form the corresponding amide or is reacted with an alcohol to form the corresponding ester.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10143272.0 | 2001-09-04 | ||
| DE10143272 | 2001-09-04 | ||
| PCT/EP2002/009728 WO2003020722A1 (en) | 2001-09-04 | 2002-08-30 | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2458699A1 true CA2458699A1 (en) | 2003-03-13 |
| CA2458699C CA2458699C (en) | 2010-10-19 |
Family
ID=7697637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2458699A Expired - Lifetime CA2458699C (en) | 2001-09-04 | 2002-08-30 | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
Country Status (30)
| Country | Link |
|---|---|
| EP (1) | EP1427730B1 (en) |
| JP (1) | JP3876254B2 (en) |
| KR (1) | KR100955589B1 (en) |
| CN (1) | CN1551881A (en) |
| AR (1) | AR036586A1 (en) |
| AT (1) | ATE332898T1 (en) |
| AU (1) | AU2002337047B2 (en) |
| BR (1) | BRPI0212137A2 (en) |
| CA (1) | CA2458699C (en) |
| CO (1) | CO5560575A2 (en) |
| CY (1) | CY1105337T1 (en) |
| DE (1) | DE50207522D1 (en) |
| DK (1) | DK1427730T3 (en) |
| EA (1) | EA007062B1 (en) |
| EC (1) | ECSP045003A (en) |
| ES (1) | ES2268093T3 (en) |
| HR (1) | HRP20040213A2 (en) |
| HU (1) | HUP0401293A3 (en) |
| IL (2) | IL160440A0 (en) |
| MX (1) | MXPA04002067A (en) |
| MY (1) | MY129751A (en) |
| NO (1) | NO328804B1 (en) |
| NZ (1) | NZ531928A (en) |
| PL (1) | PL369740A1 (en) |
| PT (1) | PT1427730E (en) |
| RS (1) | RS51012B (en) |
| UA (1) | UA76512C2 (en) |
| UY (1) | UY27427A1 (en) |
| WO (1) | WO2003020722A1 (en) |
| ZA (1) | ZA200401365B (en) |
Cited By (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008051493A3 (en) * | 2006-10-19 | 2008-07-03 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| US7414053B2 (en) | 2004-08-25 | 2008-08-19 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US7547780B2 (en) | 2004-08-25 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Dihydropteridione intermediate compounds |
| US20100099680A1 (en) * | 2007-02-01 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Pteridinone derivatives as p13-kinases inhibitors |
| US7709471B2 (en) | 2006-07-06 | 2010-05-04 | Astrazeneca Ab | Compounds |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US7750152B2 (en) | 2003-02-26 | 2010-07-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US7759347B2 (en) | 2004-06-21 | 2010-07-20 | Boehringer Ingelheim International Gmbh | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments |
| US8058270B2 (en) | 2004-08-14 | 2011-11-15 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| USRE43115E1 (en) | 2004-12-02 | 2012-01-17 | Boehringer Ingelheim International Gmbh | Process for the manufacture of fused piperazin-2-one derivatives |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US8143247B2 (en) | 2004-08-14 | 2012-03-27 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US8193188B2 (en) | 2004-07-09 | 2012-06-05 | Boehringer Ingelheim International Gmbh | Methods of using pyridodihydropyrazinones |
| US8329695B2 (en) | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
| US8445675B2 (en) | 2004-08-14 | 2013-05-21 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US8569494B2 (en) | 2009-10-26 | 2013-10-29 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
| US9155736B2 (en) | 2012-10-18 | 2015-10-13 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9346812B2 (en) | 2013-01-16 | 2016-05-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9359364B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one |
| US9358232B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| US9375443B2 (en) | 2012-02-24 | 2016-06-28 | Signal Pharmaceuticals, Llc | Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib |
| US9403829B2 (en) | 2011-12-02 | 2016-08-02 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| US9416134B2 (en) | 2014-04-16 | 2016-08-16 | Signal Pharmaceuticals, Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, as TOR kinase inhibitors |
| US9434735B2 (en) | 2014-07-14 | 2016-09-06 | Signal Pharmaceuticals, Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| US9474757B2 (en) | 2013-04-17 | 2016-10-25 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| US9493466B2 (en) | 2011-10-19 | 2016-11-15 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| US9604939B2 (en) | 2013-05-29 | 2017-03-28 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| US9623028B2 (en) | 2014-07-14 | 2017-04-18 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| US9630966B2 (en) | 2013-04-17 | 2017-04-25 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| US9782427B2 (en) | 2013-04-17 | 2017-10-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| US9956225B2 (en) | 2013-07-26 | 2018-05-01 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| US11096940B2 (en) | 2017-06-22 | 2021-08-24 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6495550B2 (en) * | 1999-08-04 | 2002-12-17 | Icagen, Inc. | Pyridine-substituted benzanilides as potassium ion channel openers |
| CA2378241A1 (en) | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Benzanilides as potassium channel openers |
| EA008778B1 (en) * | 2003-02-26 | 2007-08-31 | Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Dihydropteridinones, method for the production and use thereof in the form of drugs |
| CA2578560A1 (en) * | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinones, method for the production thereof, and use thereof as a medicament |
| JP2009503014A (en) * | 2005-08-03 | 2009-01-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dihydropteridinone in the treatment of respiratory diseases |
| DE602007008837D1 (en) | 2006-02-14 | 2010-10-14 | Vertex Pharma | AS PROTEIN KINASE INHIBITORS USEFUL DYHYDRODIAZEPINE |
| WO2007135374A1 (en) * | 2006-05-19 | 2007-11-29 | Astrazeneca Ab | Dihydropteridine compounds as anti proliferative agents |
| WO2008009909A1 (en) * | 2006-07-17 | 2008-01-24 | Astrazeneca Ab | Pteridimones as modulators of polo-like kinase |
| WO2008040951A1 (en) * | 2006-10-03 | 2008-04-10 | Astrazeneca Ab | Compounds |
| KR101157848B1 (en) * | 2007-03-22 | 2012-07-11 | 다케다 야쿠힌 고교 가부시키가이샤 | Substituted pyrimidodiazepines useful as plk1 inhibitors |
| WO2008157235A1 (en) * | 2007-06-13 | 2008-12-24 | University Of Virginia Patent Foundation | Rsk inhibitors as anti-septicemia agents |
| CA2695753A1 (en) * | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinases inhibitors |
| WO2009042711A1 (en) | 2007-09-25 | 2009-04-02 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| EP2215091B1 (en) * | 2007-12-04 | 2016-03-30 | Nerviano Medical Sciences S.r.l. | Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors |
| JP5593234B2 (en) | 2008-03-11 | 2014-09-17 | ユニバーシティー ヘルス ネットワーク | Methods of treating cancer using neuropeptide Y5R (NPY5R) antagonists |
| EP2100894A1 (en) | 2008-03-12 | 2009-09-16 | 4Sc Ag | Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors |
| EP2112152A1 (en) | 2008-04-22 | 2009-10-28 | GPC Biotech AG | Dihydropteridinones as Plk Inhibitors |
| GB0807452D0 (en) * | 2008-04-24 | 2008-05-28 | Chroma Therapeutics Ltd | PLK inhibitors |
| US8093043B2 (en) | 2008-06-04 | 2012-01-10 | New York University | β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis |
| EP2303889A1 (en) | 2008-06-18 | 2011-04-06 | F. Hoffmann-La Roche AG | Halo-substituted pyrimidodiazepines as plkl inhibitors |
| KR101787309B1 (en) | 2008-12-09 | 2017-10-18 | 길리애드 사이언시즈, 인코포레이티드 | Modulators of toll-like receptors |
| ES2661850T3 (en) | 2009-09-14 | 2018-04-04 | Gilead Sciences, Inc. | Toll type receiver modulators |
| CN102020643A (en) * | 2009-09-22 | 2011-04-20 | 上海恒瑞医药有限公司 | dihydropteridine ketone derivative, and preparation method and medicinal application thereof |
| AU2010298190A1 (en) | 2009-09-25 | 2012-05-03 | Vertex Pharmaceuticals Incorporated | Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| JP2013505927A (en) | 2009-09-25 | 2013-02-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | Method for preparing pyrimidine derivatives useful as protein kinase inhibitors |
| EP2325185A1 (en) | 2009-10-28 | 2011-05-25 | GPC Biotech AG | Plk inhibitor |
| AU2010336509A1 (en) | 2009-12-23 | 2012-07-19 | Elan Pharmaceuticals, Inc | Pteridinones as inhibitors of polo-like kinase |
| EP2536725B1 (en) | 2010-02-17 | 2015-10-28 | Boehringer Ingelheim International GmbH | Dihydropteridinones, method for production and use thereof |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013075083A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| CA2862289C (en) | 2012-02-10 | 2019-11-26 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US8865716B2 (en) | 2012-02-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Dihydropteridinones II |
| US9006226B2 (en) | 2012-02-23 | 2015-04-14 | Boehringer Ingelheim International Gmbh | Dihydropteridinones I |
| JP6052527B2 (en) * | 2013-02-21 | 2016-12-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dihydropteridinone I |
| JP6072308B2 (en) * | 2013-02-21 | 2017-02-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Dihydropteridinone II |
| EP2970305B1 (en) | 2013-03-15 | 2017-02-22 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2015004075A1 (en) * | 2013-07-09 | 2015-01-15 | Bayer Pharma Aktiengesellschaft | Modified bet-protein-inhibiting dihydroquinoxalinones and dihydropyridopyrazinones |
| BR112016001457A2 (en) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | TRANSCRIPTION FACTOR INHIBITORS AND THEIR USES |
| EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| CN103664845B (en) * | 2013-12-27 | 2016-02-10 | 湖南欧亚生物有限公司 | The preparation method of amino-2, the 3-Dihydrobenzofuranes-4-formic acid of a kind of Plk kinase inhibitor drug intermediate 7- |
| JP2017504653A (en) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| JP2017504651A (en) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Use of diazepan derivatives |
| WO2015193228A1 (en) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-protein inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with para-substituted aromatic amino- or ether groups |
| WO2015193229A1 (en) * | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-protein inhibiting 1,4-dihydropyrido[3,4-b]pyrazinones with meta-substituted aromatic amino- or ether groups |
| US11116774B2 (en) | 2014-07-11 | 2021-09-14 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of HIV |
| WO2016022902A1 (en) | 2014-08-08 | 2016-02-11 | Dana-Farber Cancer Institute, Inc. | Diazepane derivatives and uses thereof |
| EA201790369A1 (en) | 2014-09-16 | 2017-10-31 | Джилид Сайэнс, Инк. | SOLID FORMS OF THOUGH-RECEPTOR MODULATOR |
| EA201790373A1 (en) | 2014-09-16 | 2017-08-31 | Джилид Сайэнс, Инк. | METHODS OF OBTAINING MODULATORS OF TOLL-SIMILAR RECEPTORS |
| WO2016105518A1 (en) * | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| RU2750164C2 (en) | 2015-09-11 | 2021-06-22 | Дана-Фарбер Кэнсер Инститьют, Инк. | Cyanothienotriazolodiazepines and methods for their use |
| KR20180051576A (en) | 2015-09-11 | 2018-05-16 | 다나-파버 캔서 인스티튜트 인크. | Acetamide thienotriazolol diazepines and their uses |
| WO2017091673A2 (en) | 2015-11-25 | 2017-06-01 | Dana-Farber Cancer Institute, Inc. | Bivalent bromodomain inhibtors and uses thereof |
| DE102017005089A1 (en) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituted 3,4-dihydroquinoxaline-2 (1H) -one |
| DE102017005091A1 (en) | 2016-05-30 | 2017-11-30 | Bayer Pharma Aktiengesellschaft | Substituted 3,4-dihydropyrido [2,3-b] pyrazine-2 (1H) -one |
| EP3529242A1 (en) | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
| CA3080941A1 (en) * | 2017-12-22 | 2019-06-27 | Dana-Farber Cancer Institute, Inc. | Nek inhibitors and methods of use |
| CA3097774A1 (en) * | 2018-04-24 | 2019-10-31 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
| CN108610343A (en) * | 2018-06-12 | 2018-10-02 | 杨文思 | A kind of epidermal growth factor receptor inhibitor and its synthetic method for treating cancer |
| WO2020033823A1 (en) * | 2018-08-10 | 2020-02-13 | Yale University | Small-molecule pi5p4k alpha/beta inhibitors and methods of treatment using same |
| CN111039944B (en) * | 2018-10-12 | 2021-11-23 | 中国科学院合肥物质科学研究院 | MST1 kinase inhibitors and uses thereof |
| CN113637017B (en) * | 2021-08-12 | 2024-03-26 | 中国药科大学 | Compound containing dihydropterin structure, its preparation method and application |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2645152B1 (en) * | 1989-03-30 | 1991-05-31 | Lipha | 3H-PTERIDINONES-4, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM |
| CA2029651C (en) * | 1989-11-17 | 2000-06-06 | David D. Davey | Tricyclic pteridinones and a process for their preparation |
| US5698556A (en) * | 1995-06-07 | 1997-12-16 | Chan; Carcy L. | Methotrexate analogs and methods of using same |
| SK3542002A3 (en) * | 1999-09-15 | 2003-04-01 | Warner Lambert Co | Pteridinones as kinase inhibitors |
| WO2002076954A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
-
2002
- 2002-08-30 RS YUP-273/04A patent/RS51012B/en unknown
- 2002-08-30 MX MXPA04002067A patent/MXPA04002067A/en active IP Right Grant
- 2002-08-30 AU AU2002337047A patent/AU2002337047B2/en not_active Ceased
- 2002-08-30 CA CA2458699A patent/CA2458699C/en not_active Expired - Lifetime
- 2002-08-30 BR BRPI0212137A patent/BRPI0212137A2/en not_active IP Right Cessation
- 2002-08-30 EA EA200400368A patent/EA007062B1/en not_active IP Right Cessation
- 2002-08-30 EP EP02772249A patent/EP1427730B1/en not_active Expired - Lifetime
- 2002-08-30 PL PL02369740A patent/PL369740A1/en not_active Application Discontinuation
- 2002-08-30 WO PCT/EP2002/009728 patent/WO2003020722A1/en active IP Right Grant
- 2002-08-30 UY UY27427A patent/UY27427A1/en not_active Application Discontinuation
- 2002-08-30 DK DK02772249T patent/DK1427730T3/en active
- 2002-08-30 HU HU0401293A patent/HUP0401293A3/en unknown
- 2002-08-30 CN CNA028172884A patent/CN1551881A/en active Pending
- 2002-08-30 ES ES02772249T patent/ES2268093T3/en not_active Expired - Lifetime
- 2002-08-30 DE DE50207522T patent/DE50207522D1/en not_active Expired - Lifetime
- 2002-08-30 AT AT02772249T patent/ATE332898T1/en active
- 2002-08-30 PT PT02772249T patent/PT1427730E/en unknown
- 2002-08-30 JP JP2003524992A patent/JP3876254B2/en not_active Expired - Lifetime
- 2002-08-30 NZ NZ531928A patent/NZ531928A/en not_active IP Right Cessation
- 2002-08-30 UA UA2004042514A patent/UA76512C2/en unknown
- 2002-08-30 KR KR1020047003248A patent/KR100955589B1/en not_active IP Right Cessation
- 2002-08-30 IL IL16044002A patent/IL160440A0/en unknown
- 2002-09-02 MY MYPI20023275A patent/MY129751A/en unknown
- 2002-09-04 AR ARP020103334A patent/AR036586A1/en not_active Suspension/Interruption
-
2004
- 2004-02-16 NO NO20040680A patent/NO328804B1/en not_active IP Right Cessation
- 2004-02-17 IL IL160440A patent/IL160440A/en not_active IP Right Cessation
- 2004-02-19 ZA ZA200401365A patent/ZA200401365B/en unknown
- 2004-03-03 HR HR20040213A patent/HRP20040213A2/en not_active Application Discontinuation
- 2004-03-04 EC EC2004005003A patent/ECSP045003A/en unknown
- 2004-03-04 CO CO04020069A patent/CO5560575A2/en not_active Application Discontinuation
-
2006
- 2006-09-08 CY CY20061101285T patent/CY1105337T1/en unknown
Cited By (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7750152B2 (en) | 2003-02-26 | 2010-07-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same |
| US8003786B2 (en) | 2003-02-26 | 2011-08-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinone compounds |
| US7816530B2 (en) | 2003-02-26 | 2010-10-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Piperazinyl compounds |
| US7786299B2 (en) | 2003-02-26 | 2010-08-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methods for treating diseases or conditions using dihydropteridinone compounds |
| US7759347B2 (en) | 2004-06-21 | 2010-07-20 | Boehringer Ingelheim International Gmbh | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments |
| US8193188B2 (en) | 2004-07-09 | 2012-06-05 | Boehringer Ingelheim International Gmbh | Methods of using pyridodihydropyrazinones |
| US8202867B2 (en) | 2004-08-14 | 2012-06-19 | Boehringer Ingelheim International Gmbh | Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide |
| US8034816B2 (en) | 2004-08-14 | 2011-10-11 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US8143247B2 (en) | 2004-08-14 | 2012-03-27 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US7728134B2 (en) | 2004-08-14 | 2010-06-01 | Boehringer Ingelheim International Gmbh | Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament |
| US8138341B2 (en) | 2004-08-14 | 2012-03-20 | Boehringer Ingelheim International Gmbh | Intermediate compounds useful for the manufacture of dihydropteridinones |
| US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US8445675B2 (en) | 2004-08-14 | 2013-05-21 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
| US8138373B2 (en) | 2004-08-14 | 2012-03-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
| US8591895B2 (en) | 2004-08-14 | 2013-11-26 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US8058270B2 (en) | 2004-08-14 | 2011-11-15 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US7700769B2 (en) | 2004-08-25 | 2010-04-20 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7547780B2 (en) | 2004-08-25 | 2009-06-16 | Boehringer Ingelheim International Gmbh | Dihydropteridione intermediate compounds |
| US7807831B2 (en) | 2004-08-25 | 2010-10-05 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7629460B2 (en) | 2004-08-25 | 2009-12-08 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7723517B2 (en) | 2004-08-25 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| US7414053B2 (en) | 2004-08-25 | 2008-08-19 | Boehringer Ingelheim International Gmbh | Dihydropteridione derivatives, process for their manufacture and their use as medicament |
| USRE43115E1 (en) | 2004-12-02 | 2012-01-17 | Boehringer Ingelheim International Gmbh | Process for the manufacture of fused piperazin-2-one derivatives |
| US7439358B2 (en) | 2006-02-08 | 2008-10-21 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US8664222B2 (en) | 2006-02-08 | 2014-03-04 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US8188086B2 (en) | 2006-02-08 | 2012-05-29 | Boehringer Ingelheim International Gmbh | Specific salt, anhydrous and crystalline form of a dihydropteridione derivative |
| US7709471B2 (en) | 2006-07-06 | 2010-05-04 | Astrazeneca Ab | Compounds |
| WO2008051493A3 (en) * | 2006-10-19 | 2008-07-03 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
| EP2457913A3 (en) * | 2006-10-19 | 2012-08-15 | Signal Pharmaceuticals LLC | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US7981893B2 (en) | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| US8372976B2 (en) | 2006-10-19 | 2013-02-12 | Signal Pharmaceuticals, Llc | Methods of treatment comprising the administration of heteroaryl compounds |
| RU2478635C2 (en) * | 2006-10-19 | 2013-04-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Heteroaryl compounds, compositions containing them and methods of treating with use of such compounds |
| US8410100B2 (en) * | 2007-02-01 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pteridinone derivatives as PI3-kinases inhibitors |
| US20100099680A1 (en) * | 2007-02-01 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Pteridinone derivatives as p13-kinases inhibitors |
| US8329695B2 (en) | 2007-08-03 | 2012-12-11 | Boehringer Ingelheim International Gmbh | Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide |
| US9771371B2 (en) | 2008-10-27 | 2017-09-26 | Signal Pharmaceuticals, Llc | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors |
| US8492381B2 (en) | 2008-10-27 | 2013-07-23 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US8507492B2 (en) | 2008-10-27 | 2013-08-13 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitor for oncology indications and diseases associated with the mTOR/PI3K/AKT pathway |
| US10167290B2 (en) | 2008-10-27 | 2019-01-01 | Signal Pharmaceuticals, Llc | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors |
| US10683298B2 (en) | 2008-10-27 | 2020-06-16 | Signal Pharmaceuticals, Llc | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US9193692B2 (en) | 2008-10-27 | 2015-11-24 | Signal Pharmaceuticals, Llc | Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors |
| US8907087B2 (en) | 2008-10-27 | 2014-12-09 | Signal Pharmaceuticals, Llc | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors |
| US11292796B2 (en) | 2008-10-27 | 2022-04-05 | Signal Pharmaceuticals, Llc | Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors |
| US8686135B2 (en) | 2009-10-26 | 2014-04-01 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
| US9079900B2 (en) | 2009-10-26 | 2015-07-14 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
| US8569494B2 (en) | 2009-10-26 | 2013-10-29 | Signal Pharmaceuticals, Llc | Methods of synthesis and purification of heteroaryl compounds |
| US8546566B2 (en) | 2010-10-12 | 2013-10-01 | Boehringer Ingelheim International Gmbh | Process for manufacturing dihydropteridinones and intermediates thereof |
| US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
| US9370535B2 (en) | 2011-05-17 | 2016-06-21 | Boehringer Ingelheim International Gmbh | Method for treatment of advanced solid tumors |
| US11166950B2 (en) | 2011-10-19 | 2021-11-09 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| US9937170B2 (en) | 2011-10-19 | 2018-04-10 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| US9493466B2 (en) | 2011-10-19 | 2016-11-15 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| US9403829B2 (en) | 2011-12-02 | 2016-08-02 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| US9375443B2 (en) | 2012-02-24 | 2016-06-28 | Signal Pharmaceuticals, Llc | Method for treating advanced non-small cell lung cancer (NSCLC) by administering a combination of a TOR kinase inhibitor and azacitidine or erlotinib |
| US9155736B2 (en) | 2012-10-18 | 2015-10-13 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| US9557338B2 (en) | 2012-10-18 | 2017-01-31 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for tor kinase inhibitory activity |
| US9795607B2 (en) | 2013-01-16 | 2017-10-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| US9346812B2 (en) | 2013-01-16 | 2016-05-24 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| US9428509B2 (en) | 2013-01-16 | 2016-08-30 | Signal Pharmaceuticals, Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
| US10052322B2 (en) | 2013-04-17 | 2018-08-21 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one |
| US9980963B2 (en) | 2013-04-17 | 2018-05-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9630966B2 (en) | 2013-04-17 | 2017-04-25 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9505764B2 (en) | 2013-04-17 | 2016-11-29 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9359364B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b] pyrazin-2(1H)-one |
| US9358232B2 (en) | 2013-04-17 | 2016-06-07 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| US9782427B2 (en) | 2013-04-17 | 2017-10-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| US10391092B2 (en) | 2013-04-17 | 2019-08-27 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| US10183019B2 (en) | 2013-04-17 | 2019-01-22 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9827243B2 (en) | 2013-04-17 | 2017-11-28 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one |
| US9474757B2 (en) | 2013-04-17 | 2016-10-25 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| US9937169B2 (en) | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| US10052323B2 (en) | 2013-05-29 | 2018-08-21 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-(trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| US9604939B2 (en) | 2013-05-29 | 2017-03-28 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| US9795603B2 (en) | 2013-05-29 | 2017-10-24 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use |
| US9974786B2 (en) | 2013-05-29 | 2018-05-22 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their use |
| US9956225B2 (en) | 2013-07-26 | 2018-05-01 | Boehringer Ingelheim International Gmbh | Treatment of myelodysplastic syndrome |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| US10004735B2 (en) | 2014-04-16 | 2018-06-26 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| US9416134B2 (en) | 2014-04-16 | 2016-08-16 | Signal Pharmaceuticals, Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, as TOR kinase inhibitors |
| US9981971B2 (en) | 2014-04-16 | 2018-05-29 | Signal Pharmaceuticals, Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one as TOR kinase inhibitors |
| US9975898B2 (en) | 2014-04-16 | 2018-05-22 | Signal Pharmaceuticals, Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-YL)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1H)-one as tor kinase inhibitors |
| US9737535B2 (en) | 2014-04-16 | 2017-08-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines |
| US9718824B2 (en) | 2014-04-16 | 2017-08-01 | Signal Pharmaceuticals, Llc | Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof |
| US9623028B2 (en) | 2014-07-14 | 2017-04-18 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| US9434735B2 (en) | 2014-07-14 | 2016-09-06 | Signal Pharmaceuticals, Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| US9867831B2 (en) | 2014-10-01 | 2018-01-16 | Boehringer Ingelheim International Gmbh | Combination treatment of acute myeloid leukemia and myelodysplastic syndrome |
| US11096940B2 (en) | 2017-06-22 | 2021-08-24 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2458699A1 (en) | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments | |
| RU2395500C2 (en) | 2,4-pyrimidine diamines used in treating neoplastic diseases, inflammatory and immune disorders | |
| CN104884434B (en) | Amidopyrimidine derivatives for the treatment of viral infections and additional diseases | |
| ES2543216T3 (en) | Thiazolopyrimidine modulators as immunosuppressive agents | |
| ES2734288T3 (en) | Bcr-abl small molecule myristate inhibitors and methods of use | |
| ES2461967T3 (en) | Pyrrolo [2,3-d] pyrimidine compounds | |
| CA2517020A1 (en) | Dihydropteridinones, method for the production and use thereof in the form of drugs | |
| ES2293324T3 (en) | PTERIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES RELATING TO TNF-ALPHA. | |
| JP2005533028A5 (en) | ||
| US20080182845A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| JP2008505157A5 (en) | ||
| MXPA01006474A (en) | Colchinol derivatives as vascular damaging agents. | |
| US8217027B2 (en) | Sphingosine-1-phosphate receptor agonist and antagonist compounds | |
| AU2012255935B2 (en) | Compounds for use in treatment of mucositis | |
| JP2005501904A5 (en) | ||
| KR101698283B1 (en) | Process for making thienopyrimidine compounds | |
| US20160175316A1 (en) | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| JP2012506908A5 (en) | ||
| JP2022541514A (en) | NLRP3 modulator | |
| US4603133A (en) | Amides and esters of 2-[N-(morpholinoalkyl)aminosulfonyl]-6-nitrobenzoic acids and compositions useful as adjuncts to radiation therapy | |
| CN114790207A (en) | Substituted pyridyl substituted fused quinoline compounds as PI3K/MTOR inhibitors | |
| EP0391971B1 (en) | Improving toxicity profiles in chemotherapy | |
| KR20230012535A (en) | ENPP1 Modulators and Uses Thereof | |
| JP2020506168A (en) | 5- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -5-azaspiro [2.5] octane-8-carboxylic acid derivatives as novel JAK kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20220830 |